Metacrine Inc

NASDAQ:MTCR  
7.75
-0.46 (-5.60%)
Other Pre-Announcement

Metacrine Reports Business Updates And Third Quarter 2020 Financial Results

Published: 11/12/2020 11:45 GMT
(MTCR) - Metacrine Reports Business Updates and Third Quarter 2020 Financial Results.
Metacrine, Inc. - Expects to Announce Topline Results From Its Phase 1 Clinical Study in Healthy Volunteers of Met642 Before End of 2020.
Metacrine, Inc. - Qtrly Loss per Share $1.41.
Metacrine, Inc. - Qtrly Company Anticipates Beginning Met 409 Phase 2a Combination Trial in First Half of 2021.